Resistant plus susceptible tuberculosis: The undiscovered country

Journal of Infectious Diseases

Volumn 209, Issue 11, 2014, Pages 1682-1684

  Ahmad Khan, Faiz ^a   Behr, Marcel ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ISONIAZID; RIFAMPICIN;

ANTIBIOTIC SENSITIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84900545756     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu078     Document Type: Note

References (15)

1. Richardson M, Carroll NM, Engelke E, et al. Multiple Mycobacterium tuberculosis strains in early cultures from patients in a highincidence community setting. J Clin Microbiol 2002; 40: 2750-4.
2. Warren RM, Victor TC, Streicher EM, et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004; 169: 610-4.
3. Huang HY, Tsai YS, Lee JJ, et al. Mixed infection with Beijing and non-Beijing strains and drug resistance pattern of Mycobacterium tuberculosis. J Clin Microbiol 2010; 48: 4474-80.
4. Mallard K, McNerney R, Crampin AC, et al. Molecular detection of mixed infections of Mycobacterium tuberculosis strains in sputum samples from patients in Karonga District, Malawi. J Clin Microbiol 2010; 48: 4512-8.
5. Dickman KR, Nabyonga L, Kateete DP, et al. Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. BMC Infect Dis 2010; 10: 349.
6. Bryant JM, Harris SR, Parkhill J, et al. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Lancet Respir Med 2013; 1: 786-792.
7. van Rie A, Victor TC, Richardson M, et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drugresistance patterns. Am J Respir Crit Care Med 2005; 172: 636-42.
8. Shamputa IC, Jugheli L, Sadradze N, et al. Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia. Respir Res 2006; 7: 99.
9. Zetola NM, Modongo C, Moonan PK, et al. Clinical outcomes among persons with pulmonary tuberculosis disease caused by M. tuberculosis isolates with phenotypic DST heterogeneity. J Infect Dis 2014; 209: 1754-63.
10. Falzon D, Gandhi N, Migliori G, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. Eur Respir J 2012; 42: 156-68.
11. Somoskovi A, Deggim V, Ciardo D, Bloemberg GV. Diagnostic implications of inconsistent results obtained with the Xpert MTB/Rif assay in detection of Mycobacterium tuberculosis isolates with an rpoB mutation associated with low-level rifampin resistance. J Clin Microbiol 2013; 51: 3127-9.
12. Van Deun A, Aung KJ, Bola V, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol 2013; 51: 2633-40.
13. Safi H, Lingaraju S, Amin A, et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-beta-D-arabinose biosynthetic and utilization pathway genes. Nat Genet 2013; 45: 1190-7.
14. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother 2014; 69: 331-42.
15. Ford CB, Shah RR, Maeda MK, et al. Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drugresistant tuberculosis. Nat Genet 2013; 45: 784-90.